Losartan Potassium Tablets, 100 Mg Tablet
Product Images NDC 59746-335

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 100 Mg (NDC 59746-335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg

Label for Losartan Potassium Tablets, USP 100 mg by Jubilant Cadista Pharmaceuticals Inc. The label shows the product name, strength (100 mg), dosage form (tablets), quantity (30 tablets), and manufacturer information. It includes storage instructions and a caution to keep out of children’s reach. The logo "Cadista" is present, along with an NDC number partially visible.*

FDA Label Image

25mg

Losartan Potassium Tablets, USP 25 mg oral tablets label by Jubilant Cadista Pharmaceuticals Inc. The label indicates a 30-tablet count with dosage instructions to see accompanying package information. Storage instructions and manufacturer details are also provided, including keeping out of reach of children and protecting from light.*

FDA Label Image

50mg

Label for Losartan Potassium Tablets, 50 mg oral tablets from Jubilant Cadista Pharmaceuticals Inc. The label shows the active ingredient and strength, packaging of 30 tablets, storage instructions, and a note to dispense with patient information leaflet.*

FDA Label Image

Figure 1 (Figure1)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period between Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 13% with a p-value of 0.021, plotting percentage of patients on the y-axis and study months on the x-axis.*

FDA Label Image

Figure 2 (Figure2)

A line graph comparing the percentage of patients experiencing a fatal stroke over time between atenolol and losartan potassium. The x-axis represents the study duration in months, and the y-axis shows the percentage of patients with fatal stroke. The graph indicates an adjusted risk reduction of 25% with losartan potassium compared to atenolol, with a statistical significance of p=0.001.*

FDA Label Image

Figure 3 (Figure3)

Figure 3 displays a forest plot of primary endpoint events within demographic subgroups comparing losartan potassium and atenolol. It shows hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) by age, gender, race, ISH, diabetes, and history of cardiovascular disease, with symbols proportional to sample size and favoring either losartan or atenolol on the x-axis.*

FDA Label Image

Figure 4.jpg (Figure4)

A line graph comparing the percentage of patients with an event over 48 months between those taking Losartan Potassium and a placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022, with the Losartan Potassium group represented by a solid line and the placebo group by a dashed line.*

FDA Label Image

Losartan Potassium, Usp (Structure)

Chemical structure of losartan potassium, depicted with its molecular components including a tetrazole ring and chlorinated imidazole ring, indicating the active ingredient in Losartan potassium Tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.